Table 4 Theoretical protection of HPV vaccines against invasive cervical cancer in the U.S., Botswana, or Kenya, based on data in the current analysis, assuming 100 % vaccine efficacy against oncogenic HPV types represented in the vaccines. The bivalent vaccine is represented by “2X”, the quadrivalent vaccine by “4X”, and the nine-valent vaccine by “9X”

From: Invasive cervical cancers in the United States, Botswana and Kenya: HPV type distribution and health policy implications